Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. Januar 2018 07:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Presents at 2018 Biotech Conference; Oral Mucositis Drug Candidate Garners Exceptional Interest After Successful Phase 2 Trial

BEVERLY, Mass., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders of a...
03. Januar 2018 07:00 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Brilacidin Meets Key Secondary Endpoint in Phase 2 Trial, Delays Onset of Severe Oral Mucositis (SOM); Latest Results Further Support Topline Data Showing Trial Met Primary Endpoint of Reducing Incidence of SOM

BEVERLY, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented additional secondary endpoint...
27. Dezember 2017 07:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Obtains Direct Evidence of Molecular Pathways Modulation in Tumors from First Patients in Kevetrin Ph2a Ovarian Cancer Trial

BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging...
21. Dezember 2017 07:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Completes Final Patient Visit in Phase 2b Study of Oral Prurisol for Psoriasis

BEVERLY, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces all patient follow-up...
18. Dezember 2017 07:30 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Brilacidin Oral Mucositis Program Moving Forward Based Upon Positive Anchoring Phase 2 Results and Increased Brilacidin Franchise Value

BEVERLY, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today is pleased to provide an update on the...
12. Dezember 2017 08:00 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Granted European Patent for Brilacidin in the Prevention of Oral Mucositis

BEVERLY, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the European Patent...
11. Dezember 2017 07:00 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Reports Positive Topline Results from Phase 2 Placebo-Controlled Trial of Brilacidin for the Prevention of Oral Mucositis in Head and Neck Cancer Patients; Company Targets a Therapeutic Leadership Position in Global OM Market

BEVERLY, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today presented successful topline results...
30. November 2017 08:00 ET | Quelle: Innovation Pharmaceuticals, Inc.

Final Patient Completes Treatment in Innovation Pharmaceuticals Phase 2b Study of Oral Prurisol for Psoriasis

BEVERLY, Mass., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that the last patient has...
16. November 2017 08:00 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Offers Perspectives on Brilacidin as a Potential Preventative Treatment for Oral Mucositis in Head and Neck Cancer Patients

BEVERLY, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide additional...
31. Oktober 2017 10:35 ET | Quelle: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Phase 2b Psoriasis Study On-Track for Completion in December 2017; Company a Sponsor at Upcoming Symposium on Hidradenitis Suppurativa

BEVERLY, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report continued...

Vorherige Seite